A

Armata Pharmaceuticals Inc
F:TG1N

Watchlist Manager
Armata Pharmaceuticals Inc
F:TG1N
Watchlist
Price: 5 EUR 0.81% Market Closed
Market Cap: €180.8m

Operating Margin

-482.9%
Current
Improving
by 369.2%
vs 3-y average of -852%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-482.9%
=
Operating Income
$-33.2m
/
Revenue
$6.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-482.9%
=
Operating Income
€-33.2m
/
Revenue
$6.9m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Armata Pharmaceuticals Inc
AMEX:ARMP
222.4m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-482.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Armata Pharmaceuticals Inc
Glance View

Market Cap
180.8m EUR
Industry
Biotechnology

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.

TG1N Intrinsic Value
2.35 EUR
Overvaluation 53%
Intrinsic Value
Price
A
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-482.9%
=
Operating Income
$-33.2m
/
Revenue
$6.9m
What is Armata Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Armata Pharmaceuticals Inc is -482.9%, which is above its 3-year median of -852%.

How has Operating Margin changed over time?

Over the last 3 years, Armata Pharmaceuticals Inc’s Operating Margin has increased from -549.8% to -482.9%. During this period, it reached a low of -1 233.1% on Jun 30, 2024 and a high of -482.9% on Jun 30, 2025.

Back to Top